Arf1 inhibitors promote the infiltration of cytotoxic T lymphocytes into tumors by affecting lipid metabolism

In recent years, cancer immunotherapies, represented by immune checkpoint blockade (ICB), have been highly successful and have become an important basis for the future treatment of cancers. However, the absence of tumoral killer T cells and the complexity of tumor microenvironment can both affect the immunotherapeutic efficacy. Therefore, it is urgent to develop novel anti-tumor agents that can effectively promote effector T cell infiltration in tumors.